Table 1.
Selected CAR T cell clinical trials with additional modifications to enhance signal 3.
| Antigen | 2nd Genetic Modification | Cell Type | Indication | Clinical Trial ID |
|---|---|---|---|---|
| CD19 | IL-7 + CCL19 | T cells | B Cell Lymphoma | NCT03929107 |
| CD19 | IL-7 + CCL19* | T cells | Diffuse Large B Cell Lymphoma | NCT04381741 |
| CD19 | mbIL-15 | T cells | B Cell Leukemia and Lymphoma | NCT03579888 |
| EGFR | NFAT.IL-12 | T cells | Colorectal Cancer | NCT03542799 |
| ErbB | IL-4Rα/IL-2Rβ (4αβ) | T cells | Head and Neck Squamous Cell Carcinoma | NCT01818323 |
| GD2 | C7R | T cells | High Grade Glioma | NCT04099797 |
| GD2 | C7R | T cells | Solid Tumors | NCT03635632 |
| GD2 | IL-15 | T cells | Neuroblastoma | NCT03721068 |
| GD2 | IL-15 | NKT cells | Neuroblastoma | NCT03294954 |
| GPC3 | IL-7 + CCL19** | T cells | Hepatocellular Carcinoma | NCT03198546 |
| Integrin β7, BCMA, CS1, CD38 or CD138 | IL-7 + CCL19 | T cells | Multiple Myeloma | NCT03778346 |
| Nectin-4/FAP | IL-7 + CCL19 or IL-12 | T cells | Solid Tumors | NCT03932565 |
| MUC16ecto | IL-12 | T cells | Ovarian Cancer | NCT02498912 |
*patients also receive PD-1 mAb (tislelizumab).
**subset of T cells are genetically modified with different transgenes.